GlobeNewswire: Dermira, Inc. Contains the last 10 of 145 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T15:45:51ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/03/25/1759843/0/en/Dermira-Announces-Life-Unfolds-Direct-to-Consumer-Campaign-to-Highlight-QBREXZA-glycopyrronium-Cloth.html?f=22&fvtc=4&fvtv=23618Dermira Announces “Life Unfolds” Direct-to-Consumer Campaign to Highlight QBREXZA™ (glycopyrronium) Cloth2019-03-25T04:00:00Z<![CDATA[MENLO PARK, Calif., March 25, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, today announced the launch of “Life Unfolds,” a new direct-to-consumer creative campaign designed to generate awareness of QBREXZA™ (glycopyrronium) cloth as a potential treatment option for people living with primary axillary hyperhidrosis, commonly known as excessive underarm sweating. QBREXZA, the first and only, once-daily, topical prescription anticholinergic, is approved by the U.S. Food and Drug Administration (FDA) to treat adult and pediatric patients 9 years of age and older living with this chronic, medical skin condition.]]>QBREXZA is a pre-moistened, medicated cloth that comes in individually wrapped packets. QBREXZA Pouchhttps://www.globenewswire.com/news-release/2019/03/25/1759843/0/en/Dermira-Announces-Life-Unfolds-Direct-to-Consumer-Campaign-to-Highlight-QBREXZA-glycopyrronium-Cloth.htmlLife Unfolds Commercial https://www.globenewswire.com/news-release/2019/03/22/1759769/0/en/Dermira-Announces-Closing-of-Public-Offering-of-Common-Stock-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html?f=22&fvtc=4&fvtv=23618Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares2019-03-22T20:01:00Z<![CDATA[MENLO PARK, Calif., March 22, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced the closing of its previously announced underwritten public offering of 11,283,019 shares of its common stock, including 1,471,698 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock, at a price to the public of $13.25 per share. All of the shares were sold by Dermira. The aggregate gross proceeds to Dermira from the offering, before deducting the underwriting discounts and commissions and offering expenses, were approximately $149.5 million.]]>https://www.globenewswire.com/news-release/2019/03/19/1757476/0/en/Dermira-Prices-130-0-Million-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=23618Dermira Prices $130.0 Million Public Offering of Common Stock2019-03-19T23:36:06Z<![CDATA[MENLO PARK, Calif., March 19, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced the pricing of its underwritten public offering of 9,811,321 shares of its common stock at a price to the public of $13.25 per share. The gross proceeds to Dermira from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $130.0 million. In addition, Dermira has granted the underwriters a 30-day option to purchase up to an additional 1,471,698 shares of its common stock, on the same terms and conditions. All of the shares will be offered and sold by Dermira.]]>https://www.globenewswire.com/news-release/2019/03/18/1756629/0/en/Dermira-Announces-Proposed-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=23618Dermira Announces Proposed Public Offering of Common Stock2019-03-18T20:30:24Z<![CDATA[MENLO PARK, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that it intends to offer $110.0 million of its common stock in an underwritten public offering. Dermira also expects to grant to the underwriters a 30-day option to purchase up to an additional $16.5 million of its common stock in the offering. All of the shares will be offered and sold by Dermira. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.]]>https://www.globenewswire.com/news-release/2019/03/18/1756186/0/en/Dermira-Announces-Positive-Topline-Results-from-Phase-2b-Study-of-Lebrikizumab-in-Patients-with-Atopic-Dermatitis.html?f=22&fvtc=4&fvtv=23618 Dermira Announces Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis2019-03-18T11:00:00Z<![CDATA[- All three doses of lebrikizumab met primary endpoint with statistical significance- Lebrikizumab was well-tolerated; safety profile consistent with prior studies- Efficacy and safety profile support advancement into Phase 3; planned by end of 2019- Conference call and webcast today at 8:30 a.m. ET / 5:30 a.m. PT]]>https://www.globenewswire.com/news-release/2019/03/05/1748393/0/en/Dermira-to-Present-at-the-Cowen-and-Company-39th-Annual-Health-Care-Conference.html?f=22&fvtc=4&fvtv=23618Dermira to Present at the Cowen and Company 39th Annual Health Care Conference2019-03-05T21:00:00Z<![CDATA[MENLO PARK, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will present an overview of the company at the Cowen and Company 39th Annual Health Care Conference on Tuesday March 12, 2019 at 9:20 a.m. ET.]]>https://www.globenewswire.com/news-release/2019/03/01/1745247/0/en/Dermira-Presents-New-Data-from-its-Phase-3-Clinical-Program-Evaluating-Glycopyrronium-Tosylate-QBREXZA-glycopyrronium-cloth-in-Patients-with-Primary-Axillary-Hyperhidrosis.html?f=22&fvtc=4&fvtv=23618Dermira Presents New Data from its Phase 3 Clinical Program Evaluating Glycopyrronium Tosylate (QBREXZA™ (glycopyrronium) cloth) in Patients with Primary Axillary Hyperhidrosis2019-03-01T13:00:00Z<![CDATA[WASHINGTON, March 01, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today presented new post-hoc analyses from its glycopyrronium tosylate (now QBREXZA™ (glycopyrronium) cloth) Phase 3 clinical program at the Annual Meeting of the American Academy of Dermatology (AAD) in Washington, D.C. The poster presentations are now live in Hall D of the Walter E. Washington Convention Center.]]>https://www.globenewswire.com/news-release/2019/02/26/1742883/0/en/Dermira-Reports-Fourth-Quarter-and-Full-Year-2018-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=23618Dermira Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update2019-02-26T21:01:00Z<![CDATA[MENLO PARK, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today reported financial results for the quarter and year ended December 31, 2018.]]>https://www.globenewswire.com/news-release/2019/02/26/1742353/0/en/Dermira-to-Present-New-Analyses-of-the-Glycopyrronium-Tosylate-Clinical-Program-at-the-77th-American-Academy-of-Dermatology-Annual-Meeting.html?f=22&fvtc=4&fvtv=23618Dermira to Present New Analyses of the Glycopyrronium Tosylate Clinical Program at the 77th American Academy of Dermatology Annual Meeting2019-02-26T13:00:00Z<![CDATA[MENLO PARK, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, today announced that new post-hoc analyses from its glycopyrronium tosylate (QBREXZA™ (glycopyrronium) cloth) clinical program will be presented in poster format at the 77th Annual Meeting of the American Academy of Dermatology (AAD) being held in Washington, D.C., March 1-5, 2019.]]>https://www.globenewswire.com/news-release/2019/02/22/1740242/0/en/Dermira-Initiates-Proof-of-Concept-Study-to-Evaluate-QBREXZA-glycopyrronium-Cloth-in-Patients-with-Primary-Palmar-Hyperhidrosis.html?f=22&fvtc=4&fvtv=23618Dermira Initiates Proof-of-Concept Study to Evaluate QBREXZA™ (glycopyrronium) Cloth in Patients with Primary Palmar Hyperhidrosis2019-02-22T13:00:00Z<![CDATA[- Study will assess the impact of QBREXZA treatment on sweat severity in patients with primary palmar hyperhidrosis- Results will inform potential development plans for QBREXZA in primary palmar hyperhidrosis- Findings from the study are expected in the second half of 2019]]>